Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers

The development of immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death protein ligand 1 (PD-L1) has revolutionized the treatment strategy in various types of cancers. In addition, recent studies hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Eso, Yuji, Seno, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443993/
https://www.ncbi.nlm.nih.gov/pubmed/32913444
http://dx.doi.org/10.1177/1756284820948773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443993/
https://www.ncbi.nlm.nih.gov/pubmed/32913444
http://dx.doi.org/10.1177/1756284820948773

Ejemplares similares